

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity Antisense Therapeutics Limited (ASX: ANP)</b>
<b>ABN 41 095 060 745</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert W Moses
<b>Date of last notice</b>	02 November 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct												
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-												
<b>Date of change</b>	03 December 2019												
<b>No. of securities held prior to change</b>	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%;">Shares</th> <th style="width: 35%;">Options</th> </tr> </thead> <tbody> <tr> <td><b>Direct</b></td> <td>7,200,000</td> <td>1,418,888</td> </tr> <tr> <td><b>Indirect</b></td> <td>-</td> <td>-</td> </tr> <tr> <td><b>Total</b></td> <td><b>7,200,000</b></td> <td><b>1,418,888</b></td> </tr> </tbody> </table>		Shares	Options	<b>Direct</b>	7,200,000	1,418,888	<b>Indirect</b>	-	-	<b>Total</b>	<b>7,200,000</b>	<b>1,418,888</b>
	Shares	Options											
<b>Direct</b>	7,200,000	1,418,888											
<b>Indirect</b>	-	-											
<b>Total</b>	<b>7,200,000</b>	<b>1,418,888</b>											
<b>Class</b>	Ordinary shares												
<b>Number acquired</b>	800,000												
<b>Number disposed</b>	Nil												
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$64,000												

---

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>		<b>Shares</b>	<b>Options</b>
	<b>Direct</b>	8,000,000	618,888
	<b>Indirect</b>	-	-
	<b>Total</b>	<b>8,000,000</b>	<b>618,888</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Listed Options (ANPOB)		

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



The CFO Solution

03 December 2019

+ See chapter 19 for defined terms.